BIOGEN INC. Net Income (Loss) Available to Common Stockholders, Basic
BIOGEN INC. (BIIB) reported Net Income (Loss) Available to Common Stockholders, Basic of $1.86 billion for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-06.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2014-02-06
- BIOGEN INC. net income (loss) available to common stockholders, basic for the quarter ending 2012-12-31 was $292.10M, a 2.73% decline year-over-year.
- BIOGEN INC. net income (loss) available to common stockholders, basic for the quarter ending 2012-09-30 was $398.40M, a 13.25% increase year-over-year.
- BIOGEN INC. net income (loss) available to common stockholders, basic for the quarter ending 2012-06-30 was $386.80M, a 34.31% increase year-over-year.
- BIOGEN INC. net income (loss) available to common stockholders, basic for the quarter ending 2012-03-31 was $302.70M, a 3.03% increase year-over-year.
- BIOGEN INC. net income (loss) available to common stockholders, basic for fiscal 2013 was $1.86B, a 34.95% increase from fiscal 2012.
- BIOGEN INC. net income (loss) available to common stockholders, basic for fiscal 2012 was $1.38B, a 11.84% increase from fiscal 2011.
- BIOGEN INC. net income (loss) available to common stockholders, basic for fiscal 2011 was $1.23B, a 22.98% increase from fiscal 2010.
- BIOGEN INC. net income (loss) available to common stockholders, basic for fiscal 2010 was $1.00B, a 3.60% increase from fiscal 2009.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2013-12-31 | $1.86B 10-K · filed 2014-02-06 | |||
| 2012-12-31 | $292.10M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $690.50M derived: sum of 2 quarters · filed 2014-02-06 | $1.08B derived: sum of 3 quarters · filed 2014-02-06 | $1.38B 10-K · filed 2014-02-06 |
| 2012-09-30 | $398.40M 10-Q · filed 2012-10-25 | $785.20M derived: sum of 2 quarters · filed 2012-10-25 | $1.09B 10-Q · filed 2012-10-25 | $1.39B derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-06-30 | $386.80M 10-Q · filed 2012-07-24 | $689.50M 10-Q · filed 2012-07-24 | $989.80M derived: sum of 3 quarters · filed 2014-02-06 | $1.34B derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-03-31 | $302.70M 10-Q · filed 2012-05-01 | $603.00M derived: sum of 2 quarters · filed 2014-02-06 | $954.80M derived: sum of 3 quarters · filed 2014-02-06 | $1.24B derived: sum of 4 quarters · filed 2014-02-06 |
| 2011-12-31 | $300.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $652.10M derived: sum of 2 quarters · filed 2014-02-06 | $940.10M derived: sum of 3 quarters · filed 2014-02-06 | $1.23B 10-K · filed 2014-02-06 |
| 2011-09-30 | $351.80M 10-Q · filed 2012-10-25 | $639.80M derived: sum of 2 quarters · filed 2012-10-25 | $933.60M 10-Q · filed 2012-10-25 | $1.17B derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-06-30 | $288.00M 10-Q · filed 2012-07-24 | $581.90M 10-Q · filed 2012-07-24 | $821.60M derived: sum of 3 quarters · filed 2013-02-05 | $1.08B derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $293.80M 10-Q · filed 2012-05-01 | $533.60M derived: sum of 2 quarters · filed 2013-02-05 | $787.20M derived: sum of 3 quarters · filed 2013-02-05 | $1.08B derived: sum of 4 quarters · filed 2013-02-05 |
| 2010-12-31 | $239.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $493.40M derived: sum of 2 quarters · filed 2013-02-05 | $786.20M derived: sum of 3 quarters · filed 2013-02-05 | $1.00B 10-K · filed 2013-02-05 |
| 2010-09-30 | $253.60M 10-Q · filed 2011-10-28 | $546.40M derived: sum of 2 quarters · filed 2011-10-28 | $763.50M 10-Q · filed 2011-10-28 | $1.07B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $292.80M 10-Q · filed 2011-07-26 | $510.00M 10-Q · filed 2011-07-26 | $814.80M derived: sum of 3 quarters · filed 2012-02-03 | $1.09B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | $217.00M 10-Q · filed 2011-04-21 | $522.00M derived: sum of 2 quarters · filed 2012-02-03 | $799.20M derived: sum of 3 quarters · filed 2012-02-03 | $941.80M derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $305.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $582.20M derived: sum of 2 quarters · filed 2012-02-03 | $724.80M derived: sum of 3 quarters · filed 2012-02-03 | $968.40M 10-K · filed 2012-02-03 |
| 2009-09-30 | $277.20M 10-Q · filed 2010-10-26 | $419.80M derived: sum of 2 quarters · filed 2010-10-26 | $663.40M 10-Q · filed 2010-10-26 | |
| 2009-06-30 | $142.60M 10-Q · filed 2010-07-20 | $386.10M 10-Q · filed 2010-07-20 | ||
| 2008-12-31 | $781.90M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |